Drug intelligence / Profile preview

Zilbrix + Hib vaccine

Development stage
Phase 3
Lead developer
GSK
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

This is a **combination vaccine** comprising the Zilbrix (a DTPw-HBV vaccine, containing diphtheria, tetanus, whole-cell pertussis, and hepatitis B antigens) and a **Haemophilus influenzae type b (Hib) conjugate vaccine**. Zilbrix is manufactured using a new DTPw antigen source and includes reduced quantities of polyribosylribitol phosphate (PRP, the Hib component polysaccharide). The Hib conjugate component uses PRP conjugated to a protein carrier (typically tetanus toxoid), which improves immunogenicity. The vaccine is designed for active immunization of infants and young children for the prevention of diphtheria, tetanus, pertussis, hepatitis B, and invasive disease caused by Haemophilus influenzae type b, facilitating high coverage by reducing the number of injections in immunization schedules[1].

Brand names
Zilbrix/HibTritanrix-HBV/Hib
Other names
DTPw-HBV/Hib combination vaccine
02

Targets

Diphtheria toxinPRNP (Cellular Prion Protein)HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on Zilbrix + Hib vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zilbrix + Hib vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call